Annual CFF
$62.66 M
+$24.07 M+62.38%
31 December 2023
Summary:
CRISPR Therapeutics AG annual cash flow from financing activities is currently $62.66 million, with the most recent change of +$24.07 million (+62.38%) on 31 December 2023. During the last 3 years, it has fallen by -$953.49 million (-93.83%). CRSP annual CFF is now -93.83% below its all-time high of $1.02 billion, reached on 31 December 2020.CRSP Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$9.64 M
+$10.11 M+2168.67%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly cash flow from financing activities is currently $9.64 million, with the most recent change of +$10.11 million (+2168.67%) on 30 September 2024. Over the past year, it has increased by +$8.08 million (+519.54%). CRSP quarterly CFF is now -98.12% below its all-time high of $512.89 million, reached on 30 September 2020.CRSP Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$354.05 M
+$8.08 M+2.34%
30 September 2024
Summary:
CRISPR Therapeutics AG TTM cash flow from financing activities is currently $354.05 million, with the most recent change of +$8.08 million (+2.34%) on 30 September 2024. Over the past year, it has increased by +$327.84 million (+1251.17%). CRSP TTM CFF is now -71.47% below its all-time high of $1.24 billion, reached on 31 March 2021.CRSP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +62.4% | +519.5% | +1251.2% |
| 3 y3 years | -93.8% | -5.6% | -46.1% |
| 5 y5 years | -80.2% | -86.4% | +183.3% |
CRSP Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -93.8% | +62.4% | -96.8% | +2168.7% | -46.1% | +1251.2% |
| 5 y | 5 years | -93.8% | +62.4% | -98.1% | +2168.7% | -71.5% | +1251.2% |
| alltime | all time | -93.8% | +2302.8% | -98.1% | +315.6% | -71.5% | >+9999.0% |
CRISPR Therapeutics AG Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $9.64 M(-2168.7%) | $354.05 M(+2.3%) |
| June 2024 | - | -$466.00 K(-100.2%) | $345.96 M(-4.7%) |
| Mar 2024 | - | $305.93 M(+685.7%) | $363.19 M(+479.6%) |
| Dec 2023 | $62.66 M(+62.4%) | $38.94 M(+2402.5%) | $62.66 M(+139.1%) |
| Sept 2023 | - | $1.56 M(-90.7%) | $26.20 M(-34.1%) |
| June 2023 | - | $16.77 M(+210.2%) | $39.76 M(+19.2%) |
| Mar 2023 | - | $5.40 M(+118.1%) | $33.35 M(-13.6%) |
| Dec 2022 | $38.59 M(-84.6%) | $2.48 M(-83.6%) | $38.59 M(-9.0%) |
| Sept 2022 | - | $15.11 M(+46.0%) | $42.41 M(+13.1%) |
| June 2022 | - | $10.35 M(-2.8%) | $37.51 M(+5.4%) |
| Mar 2022 | - | $10.65 M(+69.1%) | $35.60 M(-85.8%) |
| Dec 2021 | $250.94 M(-75.3%) | $6.30 M(-38.3%) | $250.94 M(-61.8%) |
| Sept 2021 | - | $10.21 M(+21.0%) | $657.27 M(-43.3%) |
| June 2021 | - | $8.44 M(-96.3%) | $1.16 B(-6.5%) |
| Mar 2021 | - | $225.99 M(-45.2%) | $1.24 B(+22.1%) |
| Dec 2020 | $1.02 B | $412.63 M(-19.5%) | $1.02 B(+11.9%) |
| Sept 2020 | - | $512.89 M(+473.0%) | $908.24 M(+94.8%) |
| June 2020 | - | $89.50 M(+7806.8%) | $466.24 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $1.13 M(-99.6%) | $406.39 M(-5.7%) |
| Dec 2019 | $430.98 M(+36.4%) | $304.72 M(+329.9%) | $430.98 M(+244.8%) |
| Sept 2019 | - | $70.89 M(+139.0%) | $125.00 M(-48.4%) |
| June 2019 | - | $29.65 M(+15.3%) | $242.33 M(+12.0%) |
| Mar 2019 | - | $25.73 M(-2127.3%) | $216.41 M(-31.5%) |
| Dec 2018 | $315.93 M(>+9900.0%) | -$1.27 M(-100.7%) | $315.93 M(-0.8%) |
| Sept 2018 | - | $188.22 M(+4947.5%) | $318.49 M(+143.4%) |
| June 2018 | - | $3.73 M(-97.0%) | $130.87 M(+2.4%) |
| Mar 2018 | - | $125.25 M(+9654.8%) | $127.84 M(+4801.8%) |
| Dec 2017 | $2.61 M(-98.6%) | $1.28 M(+110.8%) | $2.61 M(-97.2%) |
| Sept 2017 | - | $609.00 K(-12.4%) | $93.09 M(+5.8%) |
| June 2017 | - | $695.00 K(+3375.0%) | $88.01 M(-40.6%) |
| Mar 2017 | - | $20.00 K(-100.0%) | $148.24 M(-19.1%) |
| Dec 2016 | $183.22 M(+89.4%) | $91.77 M(-2152.5%) | $183.22 M(+100.3%) |
| Sept 2016 | - | -$4.47 M(-107.3%) | $91.45 M(-4.7%) |
| June 2016 | - | $60.92 M(+74.1%) | $95.92 M(+174.1%) |
| Mar 2016 | - | $35.00 M | $35.00 M |
| Dec 2015 | $96.73 M(+1788.2%) | - | - |
| Dec 2014 | $5.12 M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual cash flow from financing activities?
- What is the all time high annual CFF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual CFF year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly CFF year-on-year change?
- What is CRISPR Therapeutics AG TTM cash flow from financing activities?
- What is the all time high TTM CFF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM CFF year-on-year change?
What is CRISPR Therapeutics AG annual cash flow from financing activities?
The current annual CFF of CRSP is $62.66 M
What is the all time high annual CFF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash flow from financing activities is $1.02 B
What is CRISPR Therapeutics AG annual CFF year-on-year change?
Over the past year, CRSP annual cash flow from financing activities has changed by +$24.07 M (+62.38%)
What is CRISPR Therapeutics AG quarterly cash flow from financing activities?
The current quarterly CFF of CRSP is $9.64 M
What is the all time high quarterly CFF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash flow from financing activities is $512.89 M
What is CRISPR Therapeutics AG quarterly CFF year-on-year change?
Over the past year, CRSP quarterly cash flow from financing activities has changed by +$8.08 M (+519.54%)
What is CRISPR Therapeutics AG TTM cash flow from financing activities?
The current TTM CFF of CRSP is $354.05 M
What is the all time high TTM CFF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM cash flow from financing activities is $1.24 B
What is CRISPR Therapeutics AG TTM CFF year-on-year change?
Over the past year, CRSP TTM cash flow from financing activities has changed by +$327.84 M (+1251.17%)